Our top pick for
Beginners
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy CytomX Therapeutics stock | $7.19
Own CytomX Therapeutics stock in just a few minutes.
Fact checked
CytomX Therapeutics, Inc is a biotechnology business based in the US. CytomX Therapeutics shares (CTMX) are listed on the NASDAQ and all prices are listed in US Dollars. CytomX Therapeutics employs 158 staff and has a trailing 12-month revenue of around USD$92.3 million.
How to buy shares in CytomX Therapeutics
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for CytomX Therapeutics. Find the stock by name or ticker symbol: CTMX. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CytomX Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of USD$7.19, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of CytomX Therapeutics, depending on your broker.
- Check in on your investment. Congratulations, you own a part of CytomX Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
CytomX Therapeutics share price
Use our graph to track the performance of CTMX stocks over time.CytomX Therapeutics shares at a glance
Information last updated 2020-12-26.
| Latest market close | USD$7.19 |
|---|---|
| 52-week range | USD$3.595 - USD$15.44 |
| 50-day moving average | USD$7.4476 |
| 200-day moving average | USD$7.4006 |
| Wall St. target price | USD$12.56 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-2.2 |
Buy CytomX Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy CytomX Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
CytomX Therapeutics price performance over time
Historical closes compared with the close of $7.19 from 2020-12-09
| 1 week (2021-01-12) | -5.89% |
|---|---|
| 1 month (2020-12-18) | -8.06% |
| 3 months (2020-10-19) | 7.47% |
| 6 months (2020-07-17) | -16.64% |
| 1 year (2020-01-17) | -3.62% |
|---|---|
| 2 years (2019-01-18) | -57.10% |
| 3 years (2018-01-19) | 25.55 |
| 5 years (2016-01-19) | 12.61 |
CytomX Therapeutics financials
| Revenue TTM | USD$92.3 million |
|---|---|
| Gross profit TTM | USD$57.5 million |
| Return on assets TTM | -11.9% |
| Return on equity TTM | -82.41% |
| Profit margin | -58.13% |
| Book value | $1.04 |
| Market capitalisation | USD$343 million |
TTM: trailing 12 months
Shorting CytomX Therapeutics shares
There are currently 3.7 million CytomX Therapeutics shares held short by investors – that's known as CytomX Therapeutics's "short interest". This figure is 7.2% down from 4.0 million last month.
There are a few different ways that this level of interest in shorting CytomX Therapeutics shares can be evaluated.
CytomX Therapeutics's "short interest ratio" (SIR)
CytomX Therapeutics's "short interest ratio" (SIR) is the quantity of CytomX Therapeutics shares currently shorted divided by the average quantity of CytomX Therapeutics shares traded daily (recently around 538923.82352941). CytomX Therapeutics's SIR currently stands at 6.8. In other words for every 100,000 CytomX Therapeutics shares traded daily on the market, roughly 6800 shares are currently held short.
However CytomX Therapeutics's short interest can also be evaluated against the total number of CytomX Therapeutics shares, or, against the total number of tradable CytomX Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CytomX Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 CytomX Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.0667% of the tradable shares (for every 100,000 tradable CytomX Therapeutics shares, roughly 67 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against CytomX Therapeutics.
Find out more about how you can short CytomX Therapeutics stock.
CytomX Therapeutics share dividends
We're not expecting CytomX Therapeutics to pay a dividend over the next 12 months.
CytomX Therapeutics share price volatility
Over the last 12 months, CytomX Therapeutics's shares have ranged in value from as little as $3.595 up to $15.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CytomX Therapeutics's is 0.7486. This would suggest that CytomX Therapeutics's shares are less volatile than average (for this exchange).
CytomX Therapeutics overview
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug for the treatment of metastatic melanoma; CX-2029, a PDC targeting CD71 for solid tumors; and BMS-986288, an anti-CTLA-4 Probody drug for solid tumors. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Frequently asked questions
More guides on Finder
-
How to buy Gold Royalty Corp (GROY) stock when it goes public
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
-
How to buy Bustle Digital Group (CTMX.US) stock when it goes public
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
-
How to buy Lucid Motors (CTMX.US) stock when it goes public
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
-
How to buy HF Foods Group stock | $7.55
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
-
How to buy Hannon Armstrong Sustainable Infrastructure Capital stock | $69.54
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
-
How to buy Griffin Industrial Realty stock | $65.9
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
-
How to buy FS Bancorp stock | $59.24
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
-
How to buy First Northwest Bancorp stock | $16.66
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
-
How to buy First National Corporation stock | $17.74
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
-
How to buy Farmers National Banc stock | $13.88
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
Ask an Expert